The U.S. Food and Drug Administration (FDA) has approved a new pancreatic cancer drug developed by Revolution Medicines, offering fresh hope to patients battling advanced forms of the disease.
The once-daily pill, Rasonque, was approved for patients with metastatic pancreatic cancer who have already received treatment or cannot undergo combination chemotherapy. The drug works by blocking several forms of the RAS protein, which plays a major role in the growth of many pancreatic tumors.
The approval follows a large clinical trial in which the treatment was shown to double survival rates among patients with advanced pancreatic cancer while also improving their quality of life.
Revolution Medicines said Rasonque will be available in the United States at a price of $39,800 for a 30-day supply, with financial assistance also available.
The FDA reviewed the drug through an expedited pathway designed to reduce approval timelines from the usual 10–12 months to as little as one or two months.
Doctors have described the approval as a major breakthrough in pancreatic cancer treatment. Researchers say targeting the RAS pathway could open the door to further advances against one of the most difficult cancers to treat.
The drug had already been provided to some seriously ill patients through an expanded-access programme before its full approval. Some patients reported fewer side effects and a better ability to carry out everyday activities compared with chemotherapy.
Analysts expect Rasonque to become a major treatment option, with potential global annual sales estimated at $11.5 billion.
The American Cancer Society estimates that about 67,350 people will be diagnosed with pancreatic cancer in the United States this year.
.jpeg)
.jpeg "Sunayen kofofin aljanna guda takwas 8")
0 Comment about the Post: